THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Graham, Donna M. [1 ]
Djalalov, Sandjar [2 ]
Beca, Jaclyn [2 ]
Hoch, Jeffrey [3 ]
Tsao, Ming S. [4 ]
Cutz, Jc [5 ]
Leighl, Natasha [1 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, East Melbourne, Vic, Australia
[2] Canc Care Ontario, Pharmacoecon Res Unit, Toronto, ON, Canada
[3] Canc Care Ontarior Pharmacoecon Unit, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Dept Pathol, East Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON L8S 4L8, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
cost-effectiveness; ALK-rearrangement; Crizotinib; advanced non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.24-037
引用
收藏
页码：S1317 / S1318
页数：2
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
    Djalalov, S.
    Graham, D. M.
    Beca, J.
    Hoch, J. S.
    Tsao, M. S.
    Leighl, N.
    VALUE IN HEALTH, 2014, 17 (07) : A642 - A642
  • [2] THE COST-EFFECTIVENESS OF 2ND LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NSCLC IN ONTARIO
    Djalalov, S.
    Graham, D. M.
    Beca, J.
    Hoch, J. S.
    Tsao, M. S.
    Cutz, J. C.
    Leighl, N.
    VALUE IN HEALTH, 2014, 17 (03) : A90 - A90
  • [3] COST-EFFECTIVENESS OF EML4-ALK FUSION TESTING IN COMBINATION WITH CRIZOTINIB TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER LIVING IN ONTARIO
    Djalalov, S.
    Hoch, J. S.
    Beca, J.
    Krahn, M.
    Tsao, M. S.
    Cutz, J. C.
    Leighl, N.
    VALUE IN HEALTH, 2013, 16 (03) : A142 - A142
  • [4] COST-EFFECTIVENESS OF EML4-ALK FUSION TESTING AND FIRST-LINE CRIZOTINIB TREATMENT FOR PATIENTS WITH ADVANCED ALK POSITIVE NON-SMALL CELL LUNG CANCER IN A PUBLICLY FUNDED SYSTEM (ONTARIO, CANADA)
    Djalalov, S.
    Beca, J.
    Hoch, J. S.
    Krahn, M. D.
    Tsao, M. S.
    Cutz, J. C.
    Leighl, N.
    VALUE IN HEALTH, 2013, 16 (07) : A410 - A410
  • [5] The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer
    Lin, Yen-Ting
    Liu, Yi-Nan
    Shih, Jin-Yuan
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [6] COST-EFFECTIVENESS OF LORLATINIB IN SECOND-LINE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
    Shi, S.
    Jiang, Y.
    VALUE IN HEALTH, 2023, 26 (12) : S201 - S201
  • [7] Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Djalalov, Sandjar
    Beca, Jaclyn
    Hoch, Jeffrey S.
    Krahn, Murray
    Tsao, Ming-Sound
    Cutz, Jean-Claude
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1012 - +
  • [8] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Burak Bilgin
    Mehmet Ali Nahit Şendur
    Şebnem Yücel
    Mutlu Hizal
    Gürkan Güner
    Nalan Akyürek
    Cihan Erol
    Muhammed Bülent Akıncı
    Didem Şener Dede
    Bülent Yalçın
    Sadettin Kılıçkap
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2637 - 2643
  • [9] The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
    Bilgin, Burak
    Sendur, Mehmet Ali Nahit
    Yucel, Sebnem
    Hizal, Mutlu
    Guner, Gurkan
    Akyurek, Nalan
    Erol, Cihan
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    Kilickap, Sadettin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2637 - 2643
  • [10] COST-EFFECTIVENESS OF EML4-ALK GENE TARGETED FIRST-LINE CERITINIB TREATMENT AMONG PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
    Upadhyay, N.
    Atreja, N.
    VALUE IN HEALTH, 2015, 18 (03) : A203 - A203
12345